trending Market Intelligence /marketintelligence/en/news-insights/trending/WrmKv-_o1om_Vcpg34qTcQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cabaletta Bio prices $66.2M Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cabaletta Bio prices $66.2M Nasdaq IPO

Cabaletta Bio Inc. priced its IPO of 6.8 million common shares at $11 apiece to raise about $66.2 million in net proceeds.

The biotechnology company granted the underwriters a 30-day option to buy up to an additional 1,020,000 common shares in the offering.

Cabaletta said its shares will trade on the Nasdaq Global Select Market under the CABA symbol beginning Oct. 25.

The transaction is expected to complete Oct. 29, subject to customary closing conditions.

Philadelphia-based Cabaletta is developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company previously said it plans to use the net proceeds primarily to further the clinical development of desmoglein 3 chimeric autoantibody receptor T cells, a potential therapy to counter a rare autoimmune disorder called mucosal pemphigus vulgaris.

Morgan Stanley, Cowen and Evercore ISI are acting as joint book-running managers for the offering.